about
Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological ReviewPredictive biomarkers for treatment selection: statistical considerationsPersonalized medicine using DNA biomarkers: a reviewStatistical controversies in clinical research: prognostic gene signatures are not (yet) useful in clinical practiceOptimal design and patient selection for interventional trials using radiogenomic biomarkers: A REQUITE and Radiogenomics consortium statement.Molecular biomarkers for grass pollen immunotherapy.Evaluation of a chemoresponse assay as a predictive marker in the treatment of recurrent ovarian cancer: further analysis of a prospective studyA methodological framework for drug development in rare diseases.Methods and challenges in quantitative imaging biomarker developmentBiomarker driven population enrichment for adaptive oncology trials with time to event endpoints.Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis.Optimal decision rules for biomarker-based subgroup selection for a targeted therapy in oncology.The ARCAD clinical trials program: an update and invitation.Subgroup identification for treatment selection in biomarker adaptive designPersonalized therapy in endometrial cancer: challenges and opportunities.Short-term culture of tumour slices reveals the heterogeneous sensitivity of human head and neck squamous cell carcinoma to targeted therapies.Study designs and statistical analyses for biomarker researchCombiROC: an interactive web tool for selecting accurate marker combinations of omics data.Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing.Clinical trial designs incorporating predictive biomarkers.Pitfalls and limitations in translation from biomarker discovery to clinical utility in predictive and personalised medicineBiomarker in Colorectal Cancer.Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.Clinical implications of genetic variations in the VEGF system in relation to colorectal cancer.Improving the outcomes: developing cancer therapeutics.A statistician's perspective on biomarkers in drug development.Can a treatment be licenced on the basis of post-treatment predictive biomarkers?Pragmatic issues in biomarker evaluation for targeted therapies in cancer.[The relevance of biomarkers for personalised medicine].Novel chemotherapeutics and other therapies for treating high-grade glioma.The development of biomarkers to reduce attrition rate in drug discovery focused on oncology and central nervous system.Identification of biomarker-by-treatment interactions in randomized clinical trials with survival outcomes and high-dimensional spaces.Bayesian adaptive patient enrollment restriction to identify a sensitive subpopulation using a continuous biomarker in a randomized phase 2 trial.The importance of test accuracy in economic evaluations of companion diagnostics.An optimal stratified Simon two-stage design.Identification of drug-induced toxicity biomarkers for treatment determination.Challenges in translational drug research in neuropathic and inflammatory pain: the prerequisites for a new paradigm.An adaptive clinical trials procedure for a sensitive subgroup examined in the multiple sclerosis context.Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients.Quantitative assessment of a prognostic or predictive biomarker panel.
P2860
Q26766584-72E770FA-516F-43E1-B056-0B46A99A9C2EQ26778367-C2DD54DB-CE0C-4E4C-B920-4677F4171519Q27022319-6C9700FD-D181-45E0-8F9B-5695178210A7Q28078729-0D355A20-3013-4FB4-A2AF-5B139A762C1BQ30240052-CB3240E9-2412-456C-BA43-D2A25B3F89CBQ34093047-2CE48D68-9A52-492F-BB8F-A8A8EDABB85FQ34113564-42AF2285-37A9-400D-B07D-C8F2D03188F7Q34632424-BC1A35D5-4A35-4EB8-9F2A-8B3B171943A3Q34648114-C89AA348-3244-47DC-A2E1-9C5468B3331FQ35226583-2F479C60-2978-4AD0-A563-28C4C033CAFBQ35510634-B605A97C-252B-4191-A64D-9DB9404829EEQ35723310-3C257AEE-94D7-4C63-B16C-6AF718B08DE2Q35776224-9B886C3D-E3C4-4325-B7E3-2CA53ECA1171Q35863520-5D1F134F-E5BB-4B89-8168-AC432DDF3AC7Q35911350-25D547D6-D76E-445E-B60F-654203A9DDA4Q35991729-9D5EACE1-E8AC-40A8-8438-F79C79C3D372Q36239075-43D0A15C-D75C-4395-ACB7-4DA5A6059519Q36327857-1EBE590A-80B0-4F78-B65F-9E8B51275FBDQ36392598-99DDA6B5-AB99-49BE-999F-E53628E6C96DQ36534713-B0088732-6011-409D-94E7-E075E65CBFB0Q36690546-DEC691B6-33C9-4707-BD82-D3A98D8D7B90Q37114675-68300903-FACD-4366-9C5C-05D82300C7F4Q37731264-9228BAC1-0F3E-4F20-93B4-42E2BD19A04CQ37961087-48E3EC1A-E53F-476E-9E24-E89BDD5D42C2Q37965556-DBFA23C9-FBAC-4C2E-ADD3-9F710ECB3305Q37967642-4B5B8C54-FD70-485C-89E0-BE660A65A907Q38210285-A2CFB3C0-D0C7-494E-953A-E6432530B132Q38271031-EDCD1089-BC9B-459E-BAFE-3052A330A791Q38452600-69C2BEAA-EB09-45FC-AFCC-3A867A9CCDDBQ38569802-6659E893-EFE3-4117-AA92-4646525505FFQ38907580-894A5582-BE9E-4D8C-8749-DE51233D0D88Q39175273-E656175E-41F5-4490-B07D-C08F0D913327Q39531639-7E351B5B-0C15-4BEC-B499-69E614D03A86Q40361438-0B851A1F-D628-4C04-8798-A60CB70B7766Q40877368-41140ABA-7C15-445D-9929-3B5AE2A5546AQ41011537-DF56761F-1304-4C6F-802E-C6F1263B3E94Q42359116-D72E1B07-4926-45D5-B46C-A6227D7A235FQ43763237-1448CE0C-2B01-4F59-BA07-77227DBA991FQ46253386-5CDC8EAE-B74D-4A35-9630-F0144A71D6C4Q47691525-0F51D565-A7D0-4C5C-8351-7BF8DBA6DC7B
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Integrating biomarkers in clinical trials.
@en
Integrating biomarkers in clinical trials.
@nl
type
label
Integrating biomarkers in clinical trials.
@en
Integrating biomarkers in clinical trials.
@nl
prefLabel
Integrating biomarkers in clinical trials.
@en
Integrating biomarkers in clinical trials.
@nl
P2093
P2860
P50
P356
P1476
Integrating biomarkers in clinical trials.
@en
P2093
Alastair Matheson
Axel Grothey
Daniel J Sargent
P2860
P304
P356
10.1586/ERM.10.120
P577
2011-03-01T00:00:00Z